Mipomersen: Additional Phase III data

Additional data from the double-blind, international Phase III RADICHOL 1 trial in 51 subjects showed that 4 of 34 patients treated with mipomersen had elevations in liver transaminases >3 times the upper limit of normal, with 3 patients reaching levels between 5 and 8 times the upper limit of normal. One patient discontinued the trial as a result. None of the patients had changes in other laboratory tests that would indicate hepatic dysfunction. ...